Glaukos Corporation $GKOS Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC boosted its stake in shares of Glaukos Corporation (NYSE:GKOS) by 18.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 128,210 shares of the medical instruments supplier’s stock after purchasing an additional 20,014 shares during the quarter. Voya Investment Management LLC owned approximately 0.22% of Glaukos worth $10,456,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Norges Bank bought a new position in Glaukos in the 2nd quarter worth about $76,314,000. Primecap Management Co. CA boosted its position in Glaukos by 50.0% during the 2nd quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after acquiring an additional 609,523 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Glaukos by 56.5% during the first quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock valued at $125,735,000 after purchasing an additional 461,386 shares during the period. AustralianSuper Pty Ltd acquired a new stake in Glaukos in the second quarter worth about $41,946,000. Finally, William Blair Investment Management LLC grew its position in Glaukos by 52.4% in the 2nd quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock valued at $117,347,000 after buying an additional 390,805 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Down 0.9%

NYSE:GKOS opened at $116.07 on Wednesday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $163.71. The firm has a market capitalization of $6.67 billion, a price-to-earnings ratio of -75.37 and a beta of 0.69. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average price is $95.86 and its 200 day moving average price is $93.77.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. The company had revenue of $133.54 million for the quarter, compared to analysts’ expectations of $122.55 million. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The business’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.28) EPS. On average, sell-side analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, CFO Alex R. Thurman sold 315 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total transaction of $33,075.00. Following the transaction, the chief financial officer directly owned 50,488 shares in the company, valued at $5,301,240. The trade was a 0.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total transaction of $536,350.00. Following the completion of the transaction, the director directly owned 34,905 shares in the company, valued at $3,744,259.35. This trade represents a 12.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 24,655 shares of company stock worth $2,310,025. 6.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. Truist Financial lifted their target price on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Piper Sandler reissued an “overweight” rating and issued a $61.00 price target on shares of Glaukos in a report on Wednesday, December 17th. BTIG Research raised their price objective on shares of Glaukos from $104.00 to $116.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, UBS Group upped their price target on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $114.92.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.